Wojciech Zareba

List of Publications by Citations

Source: https://exaly.com/author-pdf/9166572/wojciech-zareba-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225 papers	19,308 citations	47 h-index	138 g-index
241 ext. papers	22,695 ext. citations	6.5 avg, IF	6.02 L-index

#	Paper	IF	Citations
225	Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *New England Journal of Medicine*, **2002**, 346, 877-83	59.2	5079
224	Cardiac-resynchronization therapy for the prevention of heart-failure events. *New England Journal of Medicine*, **2009**, 361, 1329-38	59.2	2105
223	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*, **2001**, 103, 89-95	16.7	1363
222	Reduction in inappropriate therapy and mortality through ICD programming. *New England Journal of Medicine*, **2012**, 367, 2275-83	59.2	900
221	Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*, **2000**, 101, 616-23	16.7	646
220	Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *New England Journal of Medicine*, **1998**, 339, 960-5	59.2	628
219	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation*, **2011**, 123, 1061-72	16.7	559
218	Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation*, **2004**, 109, 1826-33	16.7	503
217	ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. *Circulation*, **1995**, 92, 2929-34	16.7	386
216	Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation*, **1998**, 97, 2237-44	16.7	377
215	Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. *Circulation*, **2002**, 105, 794-9	16.7	306
214	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
213	Implantable cardioverter defibrillator in high-risk long QT syndrome patients. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 337-41	2.7	242
212	Long QT syndrome and pregnancy. *Journal of the American College of Cardiology*, **2007**, 49, 1092-8	15.1	233
211	Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation*, **2008**, 117, 2184-91	16.7	229
210	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *Journal of the American College of Cardiology*, **2003**, 42, 103-9	15.1	224
209	Survival with cardiac-resynchronization therapy in mild heart failure. *New England Journal of Medicine*, **2014**, 370, 1694-701	59.2	220

208	Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation*, **2011**, 124, 1527-36	16.7	216
207	Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1249-54	27.4	216
206	Genotype-phenotype aspects of type 2 long QT syndrome. *Journal of the American College of Cardiology*, **2009**, 54, 2052-62	15.1	187
205	Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. *European Heart Journal* 2015, 36, 1735-43	9.5	177
204	Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. *Circulation*, **2012**, 125, 1988-96	16.7	138
203	Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. *Circulation*, **2016**, 134, 872-82	16.7	118
202	Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. *Circulation*, **2014**, 130, 2278-86	16.7	118
201	Long-QT syndrome after age 40. *Circulation*, **2008**, 117, 2192-201	16.7	117
200	Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. *Journal of the American College of Cardiology*, **2014**, 64, 119-25	15.1	116
199	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. *European Heart Journal*, **2020**, 41, 1414-1429	9.5	110
198	The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 1048-56	6.4	106
197	Risk of cardiac events in family members of patients with long QT syndrome. *Journal of the American College of Cardiology*, **1995**, 26, 1685-91	15.1	105
196	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *European Heart Journal*, **2018**, 39, 2314-2325	9.5	104
195	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. *Circulation*, **2020**, 141, 418-428	16.7	95
194	Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. *Annals of Noninvasive Electrocardiology*, **2001**, 6, 153-8	1.5	95
193	Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. *Heart Rhythm*, **2011**, 8, 1537-43	6.7	93
192	Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. *Journal of Cardiovascular Electrophysiology*, **2005**, 16, 1265-70	2.7	87
191	Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 785-92	6.4	85

190	Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening Arrhythmias. *Journal of the American Heart Association*, **2015**, 4, e002149	6	82
189	Arthur J. Moss (1931-2018) **2018**, 23, e12556		78
188	Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. *Journal of Cardiovascular Electrophysiology*, **2010**, 21, 893-901	2.7	76
187	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
186	Antipsychotic drugs and QT interval prolongation. *Psychiatric Quarterly*, **2003**, 74, 291-306	4.1	72
185	Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1149-53	2.7	63
184	Clinical implications for affected parents and siblings of probands with long-QT syndrome. *Circulation*, **2001**, 104, 557-62	16.7	61
183	Long QT syndrome and short QT syndrome. *Progress in Cardiovascular Diseases*, **2008**, 51, 264-78	8.5	58
182	High interobserver variability in the assessment of epsilon waves: Implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Heart Rhythm*, **2016**, 13, 208-16	6.7	55
181	Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. *Circulation*, **2011**, 123, 2784-91	16.7	53
180	Prediction of sudden and non-sudden cardiac death in post-infarction patients with reduced left ventricular ejection fraction by periodic repolarization dynamics: MADIT-II substudy. *European Heart Journal*, **2017**, 38, 2110-2118	9.5	49
179	Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): Design and Clinical Protocol. *Annals of Noninvasive Electrocardiology*, **1999**, 4, 83-91	1.5	49
178	Associations between ambient wood smoke and other particulate pollutants and biomarkers of systemic inflammation, coagulation and thrombosis in cardiac patients. *Environmental Research*, **2017**, 154, 352-361	7.9	46
177	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. *European Heart Journal*, **2015**, 36, 440-8	9.5	46
176	Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). *American Journal of Cardiology*, **2005**, 95, 1487-91	3	45
175	Correlation Method for Detection of Transient T-Wave Alternans in Digital Holter ECG Recordings. *Annals of Noninvasive Electrocardiology*, **1999**, 4, 416-424	1.5	44
174	Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. *Heart Rhythm*, **2012**, 9, 892-8	6.7	43
173	Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. *JAMA Cardiology*, **2020**, 5, 300-308	16.2	43

172	QT dynamics and variability. *Annals of Noninvasive Electrocardiology*, **2005**, 10, 256-62	1.5	42
171	Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. *Heart Rhythm*, **2006**, 3, 631-7	6.7	40
170	ECG parameters and exposure to carbon ultrafine particles in young healthy subjects. *Inhalation Toxicology*, **2009**, 21, 223-33	2.7	39
169	Genotype-specific ECG patterns in long QT syndrome. *Journal of Electrocardiology*, **2006**, 39, S101-6	1.4	38
168	Elevated particle number concentrations induce immediate changes in heart rate variability: a panel study in individuals with impaired glucose metabolism or diabetes. *Particle and Fibre Toxicology*, **2015**, 12, 7	8.4	37
167	Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. *Journal of Electrocardiology*, **2003**, 36 Suppl, 101-8	1.4	36
166	The value of electrocardiographic abnormalities in the prognosis of pulmonary embolism: a consensus paper. *Annals of Noninvasive Electrocardiology*, **2015**, 20, 207-23	1.5	34
165	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. *Clinical Research in Cardiology*, **2016**, 105, 944-952	6.1	32
164	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. *Europace*, **2015**, 17, 1259-66	3.9	32
163	Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 862-871	2.7	31
162	Asthma and the risk of cardiac events in the Long QT syndrome. Long QT Syndrome Investigative Group. *American Journal of Cardiology*, **1999**, 84, 1406-11	3	31
161	Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. *Journal of Molecular and Cellular Cardiology*, **2016**, 100, 25-34	5.8	31
160	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. *Journal of the American College of Cardiology*, **2017**, 69, 2369-2379	15.1	30
159	Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. *American Heart Journal*, **2017**, 189, 75-84	4.9	29
158	Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. *Journal of the American College of Cardiology*, **2014**, 64, 971-81	15.1	29
157	Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. *Journal of the American College of Cardiology*, **2018**, 72, 636-645	15.1	28
156	A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. *Heart Rhythm*, **2008**, 5, 11-8	6.7	28
155	Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. *American Heart Journal*, **2017**, 189, 158-166	4.9	27

154	The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). *Journal of the American College of Cardiology*, **2014**, 63, 1190-1197	15.1	26
153	Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. *American Journal of Cardiology*, **2008**, 102, 871-4	3	26
152	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 555-62	2.7	26
151	Clinical Implications of Complete Left-Sided Reverse Remodeling With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. *Journal of the American College of Cardiology*, **2016**, 68, 1268-76	15.1	26
150	Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. *Journal of the American Heart Association*, **2015**, 4,	6	25
149	Ambient and controlled exposures to particulate air pollution and acute changes in heart rate variability and repolarization. *Scientific Reports*, **2019**, 9, 1946	4.9	24
148	Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention. *American Heart Journal*, **2019**, 217, 148-158	4.9	23
147	Gene-Specific Therapy for Long QT Syndrome. *Annals of Noninvasive Electrocardiology*, **1997**, 2, 274-278	1.5	23
146	Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3). *Annals of Noninvasive Electrocardiology*, **2018**, 23, e12537	1.5	22
145	NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. *Atherosclerosis*, **2008**, 196, 461-468	3.1	22
144	Negative T wave in ischemic heart disease: a consensus article. *Annals of Noninvasive Electrocardiology*, **2014**, 19, 426-41	1.5	21
143	The effect of ICD programming on inappropriate and appropriate ICD Therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 424-433	2.7	21
142	Genetic biomarkers for the risk of seizures in long QT syndrome. *Neurology*, **2016**, 87, 1660-1668	6.5	21
141	Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 1039-44	2.7	20
140	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1799-1805	27.4	19
139	Improving clinical practice guidelines for practicing cardiologists. *American Journal of Cardiology*, **2015**, 115, 1773-6	3	19
138	Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. *Heart Rhythm*, **2015**, 12, 2010-7	6.7	18
137	Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term Outcome in Patients With Heart Failure. *American Journal of Cardiology*, **2015**, 116, 1071-5	3	18

136	Early procedure-related adverse events by gender in MADIT-CRT. *Journal of Cardiovascular Electrophysiology*, **2014**, 25, 985-989	2.7	18
135	Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction. *Circulation: Heart Failure*, **2014**, 7, 565-72	7.6	18
134	Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. *Europace*, **2019**, 21, 339-346	3.9	17
133	Proposed In-Training Electrocardiogram Interpretation Competencies for Undergraduate and Postgraduate Trainees. *Journal of Hospital Medicine*, **2018**, 13, 185-193	2.7	17
132	Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. *European Journal of Heart Failure*, **2015**, 17, 971-8	12.3	16
131	Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation?. *Environmental Research*, **2016**, 149, 15-22	7.9	16
130	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. *European Heart Journal*, **2021**, 42, 1676-1684	9.5	16
129	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. *Circulation: Heart Failure*, **2015**, 8, 725-32	7.6	15
128	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. *Circulation*, **2020**, 141, 429-439	16.7	15
127	QT-RR Slope:. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 234-235	2.7	15
126	Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1. *Heart Rhythm*, **2016**, 13, 122-31	6.7	14
125	Atrial Fibrillation in Long QT Syndrome by Genotype. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12, e007213	6.4	14
124	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. *Europace*, **2015**, 17, 1085-91	3.9	14
123	Impaired IKs channel activation by Ca(2+)-dependent PKC shows correlation with emotion/arousal-triggered events in LQT1. *Journal of Molecular and Cellular Cardiology*, **2015**, 79, 203-11	5.8	13
122	Cardiovascular function and ozone exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES). *Environment International*, **2018**, 119, 193-202	12.9	13
121	Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices. *American Journal of Cardiology*, **2017**, 119, 297-301	3	13
120	Automatic QRS Selvester scoring system in patients with left bundle branch block. *Europace*, **2016**, 18, 308-14	3.9	12
119	Comparison of age (. *American Journal of Cardiology*, **2014**, 114, 1855-60	3	12

118	Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. *Cardiovascular Diabetology*, **2016**, 15, 93	8.7	12
117	JT interval: What does this interval mean?. *Journal of Electrocardiology*, **2017**, 50, 748-751	1.4	11
116	Heart rate variability in patients with congenital long QT syndrome. *Annals of Noninvasive Electrocardiology*, **2001**, 6, 298-304	1.5	11
115	Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century. *Journal of Physiology*, **2016**, 594, 6893-6908	3.9	11
114	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. *JACC: Clinical Electrophysiology*, **2018**, 4, 1410-1420	4.6	11
113	Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure: A Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Long-Term Follow-Up Substudy. *Circulation: Heart Failure*, **2015**, 8, 921-6	7.6	10
112	Bipolar left ventricular pacing is associated with significant reduction in heart failure or death in CRT-D patients with LBBB. *Heart Rhythm*, **2016**, 13, 1468-74	6.7	10
111	Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers With Normal QTc Interval: The Value of Sex, T-Wave Morphology, and Mutation Type. *Circulation: Arrhythmia and Electrophysiology* , **2018**, 11, e005918	6.4	10
110	Acute Changes in Ambient Temperature Are Associated With Adverse Changes in Cardiac Rhythm. *Air Quality, Atmosphere and Health*, **2014**, 7, 357-367	5.6	10
109	The effect of weight loss on clinical outcomes in patients implanted with a cardiac resynchronization therapy device-A MADIT-CRT substudy. *Journal of Cardiac Failure*, **2014**, 20, 183-9	3.3	10
108	Predictive value of device-derived activity level for short-term outcomes in MADIT-CRT. *Heart Rhythm*, **2017**, 14, 1081-1086	6.7	9
107	Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy. *Circulation: Heart Failure*, **2016**, 9, e002667	7.6	9
106	Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. *Heart Rhythm*, **2016**, 13, 852-9	6.7	9
105	One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 1307-1313	1.6	9
104	Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. *European Journal of Heart Failure*, **2015**, 17, 964-70	12.3	9
103	A metric for evaluating the cardiac response to resynchronization therapy. *American Journal of Cardiology*, **2014**, 113, 1371-7	3	9
102	Dispersion of Repolarization: Time to Move Beyond QT Dispersion. *Annals of Noninvasive Electrocardiology*, **2000**, 5, 373-381	1.5	9
101	Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. *Europace*, **2015**, 17, 1816-22	3.9	8

100	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. *American Journal of Cardiology*, **2018**, 121, 615-620	3	8
99	Ventricular Electrical Delay Measured From Body Surface ECGs Is Associated With Cardiac Resynchronization Therapy Response in Left Bundle Branch Block Patients From the MADIT-CRT Trial (Multicenter Automatic Defibrillator Implantation-Cardiac Resynchronization Therapy). *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005719	6.4	8
98	Long-Term Survival of Patients With Left Bundle Branch Block Who Are Hypo-Responders to Cardiac Resynchronization Therapy. *American Journal of Cardiology*, **2017**, 120, 825-830	3	8
97	Scar burden assessed by Selvester QRS score predicts prognosis, not CRT clinical benefit in preventing heart failure event and death: A MADIT-CRT sub-study. *Journal of Electrocardiology*, **2016**, 49, 603-9	1.4	8
96	Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation. *Atherosclerosis*, **2016**, 250, 1-8	3.1	8
95	Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. *Journal of Cardiac Failure*, **2015**, 21, 541-7	3.3	7
94	Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy. *Annals of Noninvasive Electrocardiology*, **2018**, 23, e12491	1.5	7
93	Do elevated blood levels of omega-3 fatty acids modify effects of particulate air pollutants on fibrinogen?. *Air Quality, Atmosphere and Health*, **2018**, 11, 791-799	5.6	7
92	Smoking is associated with an increased risk of first and recurrent ventricular tachyarrhythmias in ischemic and nonischemic patients with mild heart failure: a MADIT-CRT substudy. *Heart Rhythm*, **2014**, 11, 822-7	6.7	7
91	Prognostic Significance of Heart Rate Variability Among Patients Treated With Cardiac Resynchronization Therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). *JACC: Clinical Electrophysiology*, **2015**, 1, 74-80	4.6	7
90	Implantable cardioverter defibrillator therapy in postinfarction patients. *Current Opinion in Cardiology*, **2004**, 19, 619-24	2.1	7
89	A counterpoint paper: Comments on the electrocardiographic part of the 2018 Fourth Universal Definition of Myocardial Infarction. *Journal of Electrocardiology*, **2020**, 60, 142-147	1.4	7
88	Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure. *Cardiology Journal*, **2010**, 17, 543-8	1.4	7
87	Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. *Heart Rhythm*, **2015**, 12, 2030-7	6.7	6
86	Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus. *American Journal of Cardiology*, **2015**, 116, 393-9	3	6
85	Do Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function?. *Annals of the American Thoracic Society*, **2020**, 17, 563-572	4.7	6
84	Abnormal Repolarization Duration During Everyday Emotional Arousal in Long QT Syndrome and Coronary Artery Disease. *American Journal of Medicine*, **2018**, 131, 565-572.e2	2.4	6
83	Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. *Journal of Cardiovascular Electrophysiology*, **2017**, 28, 94-102	2.7	6

82	Identification of Low-Risk Adult Congenital LQTS Patients. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 853-858	2.7	6
81	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. *Heart Rhythm*, **2018**, 15, 1379-1386	6.7	6
80	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. *Journal of Cardiac Failure*, **2016**, 22, 143-9	3.3	5
79	Left Ventricular Reverse Remodeling in Cardiac Resynchronization Therapy and Long-Term Outcomes. *JACC: Clinical Electrophysiology*, **2019**, 5, 1001-1010	4.6	5
78	Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT). *American Journal of Cardiology*, **2015**, 115, 1423-7	3	5
77	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy	3	5
76	The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Europace*, **2018**, 20, 794-800	3.9	5
75	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. *Europace*, **2019**, 21, 1843-1850	3.9	5
74	Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 879-884	2.7	5
73	Effects of Statins on First and Recurrent Supraventricular Arrhythmias in Patients With Mild Heart Failure (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). *American Journal of Cardiology*, **2015**, 116, 1869-74	3	5
72	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. *European Heart Journal*, **2021**,	9.5	5
71	Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADIT-RIT substudy. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 1405-1411	1.6	4
70	Prenatal and recent methylmercury exposure and heart rate variability in young adults: the Seychelles Child Development Study. *Neurotoxicology and Teratology*, **2019**, 74, 106810	3.9	4
69	Initiation of dialysis: Trigger or cause of cardiovascular events?. *Kidney International*, **2015**, 88, 942-4	9.9	4
68	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. *Heart Rhythm*, **2014**, 11, 1001-7	6.7	4
67	Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 9-16	1.6	4
66	Quality of life predicting long-term outcomes in cardiac resynchronization therapy patients. *Europace*, **2019**, 21, 1865-1875	3.9	4
65	Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care - results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial.. *Archives of Medical Science*, **2021**, 17, 1599-1612	2.9	4

64	The Burden and Morphology of Premature Ventricular Contractions and their Impact on Clinical Outcomes in Patients Receiving Biventricular Pacing in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Annals of Noninvasive Electrocardiology*, **2016**, 21, 41-8	1.5	4
63	An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial. *ESC Heart Failure*, **2021**, 8, 1263-1273	3.7	4
62	Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. *American Journal of Cardiology*, **2018**, 121, 182-187	3	4
61	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. *PACE - Pacing and Clinical Electrophysiology*, **2020**, 43, 1495-1500	1.6	3
60	Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD. *Annals of Noninvasive Electrocardiology*, **2020**, 25, e12744	1.5	3
59	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. *Journal of Interventional Cardiac Electrophysiology*, **2018**, 52, 185-194	2.4	3
58	Effects of intranasal kinetic oscillation stimulation on heart rate variability. *Annals of Noninvasive Electrocardiology*, **2018**, 23, e12474	1.5	3
57	Predictors of long-term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. *Clinical Cardiology*, **2018**, 41, 1358-1366	3.3	3
56	Quantitative T-wave morphology assessment from surface ECG is linked with cardiac events risk in genotype-positive KCNH2 mutation carriers with normal QTc values. *Journal of Cardiovascular Electrophysiology*, **2019**, 30, 2907-2913	2.7	3
55	Comparison of low versus high (>40 mm Hg) pulse pressure to predict the benefit of cardiac resynchronization therapy for heart failure (from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Trial). *American Journal of Cardiology*, **2014**, 114, 1053-8	3	3
54	Population-based beat-to-beat QT analysis from Holter recordings in the long QT syndrome. *Journal of Electrocardiology*, **2017**, 50, 787-791	1.4	3
53	Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial. *Journal of Clinical Medicine*, **2020**, 9	5.1	3
52	Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling. *Data in Brief*, **2016**, 8, 98-104	1.2	3
51	Sex and Genotype in Long QT Syndrome Risk Stratification. *JAMA Cardiology*, **2019**, 4, 254-255	16.2	3
50	Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT. *Heart Rhythm*, **2021**, 18, 399-403	6.7	3
49	Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT. *JACC: Clinical Electrophysiology*, **2019**, 5, 1172-1181	4.6	2
48	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. *Annals of Noninvasive Electrocardiology*, **2017**, 22,	1.5	2
47	Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome. *Journal of the American College of Cardiology*, **2021**, 78, 2076-2088	15.1	2

46	Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients. *Cardiology Journal*, **2015**, 22, 519-26	1.4	2
45	A counterpoint paper: Comments on the electrocardiographic part of the 2018 Fourth Universal Definition of Myocardial Infarction endorsed by the International Society of Electrocardiology and the International Society for Holter and Noninvasive Electrocardiology. *Annals of Noninvasive Electrocardiology*, **2020**, 25, e12786	1.5	2
44	Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. *Europace*, **2020**, 22, 1384-1390	3.9	2
43	Risk Prediction in Women With Congenital Long QT Syndrome. *Journal of the American Heart Association*, **2021**, 10, e021088	6	2
42	Management of Congenital Long-QT Syndrome: Commentary From the Experts. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e009726	6.4	2
41	Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients-Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) randomized clinical trial. *Annals of Noninvasive Electrocardiology*, **2021**, 26, e12887	1.5	2
40	Which patients with chronic heart failure should be referred for CRT-D implantation? Practical implications of current clinical research **2010**, 120, 95-102		2
39	The QT Scale: A Weight Scale Measuring the QTc Interval. *Annals of Noninvasive Electrocardiology*, **2017**, 22,	1.5	1
38	Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients. *Journal of Clinical Lipidology*, **2017**, 11, 215-223	4.9	1
37	Quantifying Disease Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Key to Advancing Therapy. *JAMA Cardiology*, **2017**, 2, 303-304	16.2	1
36	Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutyifa et al. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 1280	6.4	1
35	Time-Dependent Gender Differences in the Clinical Course of Patients with the Congenital Long-QT Syndrome	28-36	
34	The Relation of QT Dispersion to Spontaneous Ventricular Arrhythmias During the Acute Phase of Myocardial Infarction **2008**, 3, 119-124		1
33	What to Expect from Electrocardiology at the Beginning of 2000?. *Annals of Noninvasive Electrocardiology*, **2000**, 5, 1-3	1.5	1
32	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment-Authors' reply.. *Europace*, **2022**,	3.9	1
31	Prognostic Usefulness of Systolic Blood Pressure One-Year Following Cardiac Resynchronization Therapy (from MADIT-CRT). *American Journal of Cardiology*, **2020**, 125, 777-782	3	1
30	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. *Journal of the American Heart Association*, **2020**, 9, e016398	6	1
29	Autonomic and Cardiac Repolarization Lability in Long QT Syndrome Patients. *Autonomic Neuroscience: Basic and Clinical*, **2020**, 229, 102723	2.4	1

28	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. *Annals of Noninvasive Electrocardiology*, **2021**, 26, e12847	1.5	1
27	Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. *Cardiovascular Diabetology*, **2021**, 20, 106	8.7	1
26	Telehealth for the Management of Left Ventricular Assist Device Patients: The University of Rochester TeleLVAD Study. *Journal of Cardiac Failure*, **2021**, 27, 112-113	3.3	1
25	Utility of cardiovascular implantable electronic device-derived patient activity to predict clinical outcomes. *Heart Rhythm*, **2021**, 18, 1344-1351	6.7	1
24	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary Implantable Cardioverter-Defibrillator Therapy. *JACC: Clinical Electrophysiology*, **2021**,	4.6	1
23	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). *Europace*, **2021**,	3.9	1
22	Genetic Variant Score and Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Plakophilin-2 Mutation Carriers. *Cardiology*, **2021**, 146, 763-771	1.6	1
21	Counting mRNA in blood of LQTS - new direction?. *Kardiologia Polska*, **2011**, 69, 430	0.9	1
20	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block: The Long-Term Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy. *Circulation: Heart Failure*, **2020**, 13, e006925	7.6	0
19	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). *Heart Rhythm O2*, **2020**, 1, 77-82	1.5	0
18	Effectiveness of high rate and delayed detection ICD programming by race: A MADIT-RIT substudy. *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1418-1424	2.7	0
17	Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. *American Journal of Cardiology*, **2020**, 132, 79-86	3	0
16	Markers of ventricular repolarization and overall mortality in sleep disordered breathing.. *Sleep Medicine*, **2022**, 95, 9-15	4.6	0
15	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. *Journal of Cardiovascular Electrophysiology*, **2020**, 31, 1099-1104	2.7	
14	Marital Status and Long-Term Outcomes in Mild Heart Failure Patients With an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator. *American Journal of Cardiology*, **2020**, 125, 1180-1186	3	
13	ARTHUR J. MOSS MD. *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 511-513	2.7	
12	Time Dependence of Ventricular Tachyarrhythmias After Myocardial Infarction: A MADIT-CRT Substudy. *JACC: Clinical Electrophysiology*, **2016**, 2, 565-573	4.6	
11	Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT). *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1017-1023	2.7	

10	Response to letter regarding article, "syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study". *Circulation*, **2014**, 130, e133	16.7
9	The Clinical Significance of Somatic Pain Tolerance in Patients with Coronary Artery Disease. *Annals of Noninvasive Electrocardiology*, **1997**, 2, 338-345	1.5
8	Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program.. *Journal of Interventional Cardiac Electrophysiology*, **2022**, 1	2.4
7	AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol. *Heart Rhythm O2*, **2020**, 1, 376-384	1.5
6	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. *Circulation: Arrhythmia and Electrophysiology*, **2020**, 13, e008499	6.4
5	479 The association of QTc and QT Variability with Severity of Sleep Disordered Breathing. *Sleep*, **2021**, 44, A189-A189	1.1
4	478 The Relationship between Sleep Disordered Breathing, Markers of Ventricular Repolarization and Cardiovascular Mortality. *Sleep*, **2021**, 44, A188-A189	1.1
3	Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up - subanalysis of the TELEREHabilitation in Heart Failure Patients randomized clinical trial.. *Archives of Medical Science*, **2022**, 18, 293-306	2.9
2	Hospitalization for Heart Failure and Subsequent Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. *JACC: Clinical Electrophysiology*, **2021**, 7, 1099-1107	4.6
1	Heart Failure Patients Adherence to Hybrid Comprehensive Telerehabilitation and Its Impact on Prognosis Based on Data from TELEREH-HF Randomized Clinical Trial. *Applied Sciences (Switzerland)* , **2022**, 12, 2595	2.6